[go: up one dir, main page]

WO2011159129A3 - 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물 - Google Patents

신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물 Download PDF

Info

Publication number
WO2011159129A3
WO2011159129A3 PCT/KR2011/004445 KR2011004445W WO2011159129A3 WO 2011159129 A3 WO2011159129 A3 WO 2011159129A3 KR 2011004445 W KR2011004445 W KR 2011004445W WO 2011159129 A3 WO2011159129 A3 WO 2011159129A3
Authority
WO
WIPO (PCT)
Prior art keywords
rhodanine derivatives
prevention
treatment
pharmaceutical composition
active ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/004445
Other languages
English (en)
French (fr)
Other versions
WO2011159129A2 (ko
Inventor
유지창
한균희
이철호
송두나
정구환
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avixgen Inc
Original Assignee
Avixgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avixgen Inc filed Critical Avixgen Inc
Priority to EP11795995.7A priority Critical patent/EP2583969A4/en
Priority to JP2013515269A priority patent/JP2013528646A/ja
Priority to CN2011800301855A priority patent/CN103003271A/zh
Priority to US13/805,326 priority patent/US8759536B2/en
Publication of WO2011159129A2 publication Critical patent/WO2011159129A2/ko
Publication of WO2011159129A3 publication Critical patent/WO2011159129A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 AIDS 예방 또는 치료용 약학 조성물에 관한 것이다. 본 발명에 따른 로다닌 유도체는 HIV 바이러스 발현을 억제함으로써 HIV 저해 활성이 우수하여 AIDS 예방 또는 치료에 유용하게 사용될 수 있다.
PCT/KR2011/004445 2010-06-18 2011-06-17 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물 Ceased WO2011159129A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP11795995.7A EP2583969A4 (en) 2010-06-18 2011-06-17 NEW RHODANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS WITH THE RHODANIN DERIVATIVES AS ACTIVE AGENTS
JP2013515269A JP2013528646A (ja) 2010-06-18 2011-06-17 新規なロダニン誘導体、その製造方法、及びそれを有効成分として含有するエイズ（ａｉｄｓ）予防又は治療用薬学組成物
CN2011800301855A CN103003271A (zh) 2010-06-18 2011-06-17 新型罗丹宁衍生物及其制备方法，含罗丹宁衍生物为活性成分的预防或治疗aids的药物组合物
US13/805,326 US8759536B2 (en) 2010-06-18 2011-06-17 Rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100057967A KR101159000B1 (ko) 2010-06-18 2010-06-18 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물
KR10-2010-0057967 2010-06-18

Publications (2)

Publication Number Publication Date
WO2011159129A2 WO2011159129A2 (ko) 2011-12-22
WO2011159129A3 true WO2011159129A3 (ko) 2012-04-26

Family

ID=45348766

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/004445 Ceased WO2011159129A2 (ko) 2010-06-18 2011-06-17 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물

Country Status (6)

Country Link
US (1) US8759536B2 (ko)
EP (1) EP2583969A4 (ko)
JP (1) JP2013528646A (ko)
KR (1) KR101159000B1 (ko)
CN (1) CN103003271A (ko)
WO (1) WO2011159129A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493452B2 (en) 2011-03-24 2016-11-15 Southern Methodist University Compounds and derivatives of 2H-pyrido (3,2-b)(1, 4) oxazin 3)4H)-ones as raf kinase and LRRK2 inhibitors
US8669363B2 (en) 2011-03-24 2014-03-11 Southern Methodist University Quinoxaline compounds and derivatives
WO2013142831A1 (en) * 2012-03-23 2013-09-26 Southern Methodist University Methods of making and using thioxothiazolidine and rhodanine derivatives as hiv-1 and jsp-1 inhibitors
WO2015023827A1 (en) * 2013-08-14 2015-02-19 North Carolina Central University A high-throughput assay for identifying small molecules that modulate amp-activated protein kinase (ampk)
CN109111408B (zh) * 2017-06-26 2021-03-09 中国科学技术大学 噻唑啉酮杂环化合物、其制备方法、药用组合物及应用
WO2019126568A1 (en) * 2017-12-22 2019-06-27 Asellus Therapeutics, L.L.C. Nifuroxazide analogs and therapeutic uses thereof
KR101893988B1 (ko) 2018-05-16 2018-08-31 (주)에빅스젠 로다닌 유도체를 함유하는 aids 예방 또는 치료용 약학 조성물
KR102224999B1 (ko) * 2018-07-25 2021-03-10 (주)에빅스젠 로다닌 유도체를 유효성분으로 포함하는 골관절염 예방, 개선 또는 치료용 약학적 조성물
CN111995622B (zh) * 2020-08-20 2022-04-15 复旦大学 化合物及其用途
CN115444846A (zh) * 2022-09-01 2022-12-09 中国人民解放军军事科学院军事医学研究院 HIV-1Tat蛋白抑制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059243A1 (en) * 2007-11-01 2009-05-07 The Uab Research Foundation Treating and preventing viral infections
US7566732B2 (en) * 2003-10-28 2009-07-28 Rigel Pharmaceuticals, Inc. Rhodanine compositions for use as antiviral agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0770095A (ja) * 1993-09-03 1995-03-14 Ono Pharmaceut Co Ltd ロダニン誘導体
IL141456A0 (en) * 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
AU3111700A (en) * 1998-12-04 2000-06-19 Structural Bioinformatics Inc. Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity
US20050042674A9 (en) 2002-02-21 2005-02-24 Lin Yu Common ligand mimics: thiazolidinediones and rhodanines
US20040002526A1 (en) * 2002-04-03 2004-01-01 Cell Therapeutics, Inc. Phospholipase D inhibitors and uses thereof
US20040214872A1 (en) * 2002-09-26 2004-10-28 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
EP1654380A4 (en) * 2003-08-14 2009-09-09 Insight Biopharmaceuticals Ltd METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF
US7718680B2 (en) * 2004-09-23 2010-05-18 Burnham Institute For Medical Research Inhibition of lethal factor protease activity from anthrax toxin
WO2006095713A1 (ja) * 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
KR100814109B1 (ko) 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
US8183236B2 (en) * 2007-04-12 2012-05-22 University Of Southern California Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics
WO2011050211A2 (en) * 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
CN102078318A (zh) * 2009-11-27 2011-06-01 华东理工大学 5-取代-2，4-噻唑烷二酮类化合物在制备igf1r功能调节药物中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566732B2 (en) * 2003-10-28 2009-07-28 Rigel Pharmaceuticals, Inc. Rhodanine compositions for use as antiviral agents
WO2009059243A1 (en) * 2007-11-01 2009-05-07 The Uab Research Foundation Treating and preventing viral infections

Also Published As

Publication number Publication date
WO2011159129A2 (ko) 2011-12-22
EP2583969A4 (en) 2013-10-23
KR20110137939A (ko) 2011-12-26
CN103003271A (zh) 2013-03-27
US8759536B2 (en) 2014-06-24
US20130096125A1 (en) 2013-04-18
EP2583969A2 (en) 2013-04-24
JP2013528646A (ja) 2013-07-11
KR101159000B1 (ko) 2012-06-21

Similar Documents

Publication Publication Date Title
WO2011159129A3 (ko) 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물
WO2012021796A3 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
WO2012009715A3 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
WO2011159137A3 (ko) 신규한 티오우레아 또는 우레아 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물
WO2012046030A3 (en) Phosphodiesterase inhibitors
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
WO2012104263A3 (en) 1,4 oxazines as bace1 and/or bace2 inhibitors
MX350746B (es) Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral.
IN2012DN01233A (ko)
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
MY185491A (en) Macrocylic pyrimidine derivatives
WO2010057101A3 (en) Compounds useful as hiv blockers
WO2014048940A3 (en) Nitrogen-containing heterocyclic compounds for plant disease control
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
WO2010147830A3 (en) Aminothiazole modulators of beta-3-adrenoreceptor
WO2009036341A3 (en) Compositions and methods relating to hiv protease inhibition
WO2011049327A3 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2011149288A2 (ko) 복수의 타이로신 카이네이즈에 대한 저해 활성을 가지는 항염증 화합물 및 이를 포함하는 약학적 조성물
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
WO2012161497A3 (ko) 보습능이 우수한 펩타이드 유도체 및 이의 용도
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2011080254A3 (en) Fungicide hydroximoyl-heterocycles derivatives
WO2011149301A3 (en) A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases
WO2012019428A8 (zh) 二苯甲醇类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11795995

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013515269

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13805326

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011795995

Country of ref document: EP